Here are four things to know.
1. The Partnership for Accelerating Cancer Therapies is part of the Cancer Moonshot program launched under the Obama administration.
2. Through the $215 million initiative, researchers will study chemical signatures in the body that help identify patients who will benefit from cancer immunotherapy.
3. Participating drugmakers include AbbVie, Roche, Bristol-Myers Squibb, Pfizer, Johnson & Johnson, Amgen, Celgene Corp., Gilead Sciences and GlaxoSmithKline. Merck, which sells the popular cancer immunotherapy Keytruda, is not involved with the initiative.
4. Drug companies will contribute $55 million to the research initiative, and NIH will provide the remaining $160 million, based on the availability of funds.
More articles on data analytics & precision medicine:
8 things to know about gene-editing tech CRISPR
Louisiana State U, Moffitt Cancer Center partner to address racial disparities in precision medicine
Survey: Healthcare execs name data analytics, population health among top challenges for 2018
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
